CD38 — a new target in renal immune disease,Nature Reviews Nephrology

当前位置： X-MOL 学术 › Nat. Rev. Nephrol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CD38 — a new target in renal immune disease
Nature Reviews Nephrology ( IF 28.6 ) Pub Date : 2024-07-23 , DOI: 10.1038/s41581-024-00874-6
Ton J Rabelink _{1,

2} , Aiko P J de Vries _{1,

2}

Affiliation

Targeting of CD38 has been posited as a potential therapeutic avenue for the treatment of immune-mediated conditions. A phase 2 study now reports promising safety, tolerability and intermediate endpoint of efficacy outcomes with the anti-CD38 monoclonal antibody felzartamab in kidney transplant recipients with antibody-mediated rejection.

中文翻译：